The Role of CSF Biomarkers in Discriminating Between Cerebral Amyloid Angiopathy and Alzheimer’s Disease Patients: Systematic Review of Clinical Studies (original) (raw)

Abstract

Background: Alzheimer disease (AD), the most prevalent cause of dementia, is characterized by cognitive impairments and gradual memory loss. One of the most common neurological disorders affecting older people is cerebral amyloid angiopathy (CAA), which is defined by the buildup of amyloid β (Aβ) peptides in the walls of small and medium-sized cerebrocortical blood vessels as well as the leptomeninges. CAA and AD have several molecular, pathological, and clinical commonalities, like levels of Aβ peptides, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF). Objectives: The main objective of this study is to compare Aβ and tau protein indicators in the CSF of individuals with CAA or AD versus a healthy control group. Materials & Methods: Medline, Web of Science, Google Scholar, and Embase databases were searched for relevant studies published from 2009 to 2022. Ten observational studies that reported the levels of t-tau, p-tau, Aβ40, Aβ42, or Aβ42/Aβ40 ratio in the CSF of AD and CCA patients were included. Results: The results showed that CAA and AD patient groups have higher p-tau and t-tau levels than the control group. Significantly lower concentrations of t-tau, p-tau, and Aβ40 are observed in the CSF of CAA compared to AD patients. Conclusion: We found that CSF p-tau, t-tau, and Aβ40 levels as reliable biomarkers can help diagnose and differentiate AD and CAA. Our study indicates that CSF biomarkers t-tau, p-tau, Aβ40, and Aβ42/Aβ40 ratio can be used in the clinical setting to distinguish between CAA and AD.

Figures (6)

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (55)

  1. Ittner LM, Götz J. Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011; 12(2):65-72. [DOI:10.1038/nrn2967] [PMID]
  2. Chang HY, Sang TK, Chiang AS. Untangling the Tauopathy for Alzheimer's disease and parkinsonism. J Biomed Sci. 2018; 25(1):54. [DOI:10.1186/s12929-018-0457-x] [PMID]
  3. Yamada M. Cerebral amyloid angiopathy: Emerg- ing concepts. J Stroke. 2015; 17(1):17-30. [DOI:10.5853/ jos.2015.17.1.17] [PMID]
  4. Greenberg SM, Cho HS, O'Donnell HC, Rosand J, Segal AZ, Younkin LH, et al. Plasma beta-amyloid peptide, transforming growth factor-beta 1, and risk for cerebral amyloid angiopathy. Ann N Y Acad Sci. 2000; 903:144-9. [DOI:10.1111/j.1749-6632.2000.tb06361.x] [PMID]
  5. Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, et al. Predominant deposition of amyloid- beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol. 1996; 148(4):1257-66. [PMID]
  6. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Pro- gression of cerebral amyloid angiopathy: Accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neu- rol. 1998; 57(4):353-9. [DOI:10.1097/00005072-199804000- 00008] [PMID]
  7. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009; 66(2):245-9. [DOI:10.1002/ana.21694] [PMID]
  8. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron. 1994; 13(1):45-53. [DOI:10.1016/0896-6273(94)90458-8] [PMID]
  9. Banerjee G, Ambler G, Keshavan A, Paterson RW, Foiani MS, Toombs J, et al., Cerebrospinal fluid biomarkers in cer- ebral amyloid angiopathy. J Alzheimers Dis. 2020; 74(4):1189- 201. [DOI:10.3233/JAD-191254] [PMID]
  10. Renard D, Wacongne A, Ayrignac X, Charif M, Fourcade G, Azakri S, et al. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in cerebral amyloid angiopathy-related inflam- mation. J Alzheimers Dis. 2016; 50(3):759-64.[DOI:10.3233/ JAD-150621] [PMID]
  11. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, et al. Impact of the 2008-2012 French Alz- heimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: The PLM Study. J Alzheimers Dis. 2013; 34(1):297-305. [DOI:10.3233/JAD-121549] [PMID]
  12. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al., Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzhei- mer's disease. Ann Neurol. 1995; 38(4):643-8. [DOI:10.1002/ ana.410380413] [PMID]
  13. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences between early-and late- onset alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. [DOI:10.1001/arch- neur.56.6.673] [PMID]
  14. Margraf NG, Jensen-Kondering U, Weiler C, Leypoldt F, Maetzler W, Philippen S, et al. Cerebrospinal fluid biomark- ers in cerebral amyloid angiopathy: New data and quantita- tive meta-analysis. Front Aging Neurosci. 2022; 14:783996. [DOI:10.3389/fnagi.2022.783996] [PMID] [15] Janson ChG. AD and CAA: Independent risk factors for de- mentia. Sci Transl Med. 2015; 7(318):318ec214. [DOI:10.1126/ scitranslmed.aad9005]
  15. Li YF, Ge FF, Zhang Y, You H, Zhang ZX. Cerebrospinal fluid biomarkers in dementia patients with cerebral amyloid angiopathy. Chin Med Sci J. 2015; 30(3):170-3. [DOI:10.1016/ S1001-9294(15)30042-0] [PMID]
  16. Marazuela P, Solé M, Bonaterra-Pastra A, Pizarro J, Cama- cho J, Martínez-Sáez E, et al. MFG-E8 (LACTADHERIN): A novel marker associated with cerebral amyloid angiopathy. Acta Neuropathol Commun. 2021; 9(1):1-17. [DOI:10.1186/ s40478-021-01257-9]
  17. Renard D, Gabelle A, Hirtz C, Demattei C, Thouvenot E, Lehmann S. Cerebrospinal fluid Alzheimer's disease bio- markers in isolated supratentorial cortical superficial sidero- sis. J Alzheimers Dis. 2016. 54(4):1291-5. [DOI:10.3233/JAD- 160400] [PMID]
  18. Grangeon L, Paquet C, Guey S, Zarea A, Martinaud O, Rot- harmel M,et al. Cerebrospinal fluid profile of tau, phosphoryl- ated tau, Aβ 42, and Aβ 40 in probable cerebral amyloid angi- opathy. J Alzheimers Dis. 2022; 87(2):791-802. [DOI:10.3233/ JAD-215208] [PMID]
  19. Renard D, Castelnovo G, Wacongne A, Le Floch A, Thou- venot E, Mas J, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol. 2012; 259(11):2429-33. [DOI:10.1007/s00415-012-6520-8] [PMID]
  20. Charidimou A, Friedrich JO, Greenberg SM, Viswana- than A. Core cerebrospinal fluid biomarker profile in cer- ebral amyloid angiopathy: A meta-analysis. Neurology. 2018; 90(9):e754-62. [DOI:10.1212/WNL.0000000000005030] [PMID]
  21. Martínez-Lizana E, Carmona-Iragui M, Alcolea D, Gómez- Choco M, Vilaplana E, Sánchez-Saudinós MB, et al. Cerebral amyloid angiopathy-related atraumatic convexal subarach- noid hemorrhage: An ARIA before the tsunami. J Cereb Blood Flow Metab. 2015; 35(5):710-7. [DOI:10.1038/jcbfm.2015.25] [PMID]
  22. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging. 2004; 25(5):589-97; discussion 603-4. [DOI:10.1016/j.neurobiolaging.2004.02.003] [PMID]
  23. Weller RO, Nicoll JA. Cerebral amyloid angiopathy: Patho- genesis and effects on the ageing and Alzheimer brain. Neu- rol Res. 2003; 25(6):611-6. [DOI:10.1179/016164103101202057 ] [PMID]
  24. Layfield R, Alban A, Mayer RJ, Lowe J. The ubiquitin pro- tein catabolic disorders. Neuropathol Appl Neurobiol. 2001; 27(3):171-9. [DOI:10.1046/j.1365-2990.2001.00335.x] [PMID]
  25. Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: Defining the perivascular route for the elimination of amyloid β from the human brain. Neuropathol Appl Neurobiol. 2003; 29(2):106-17. [DOI:10.1046/j.1365- 2990.2003.00424.x] [PMID]
  26. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: Amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol. 1998; 153(3):725-33. [DOI:10.1016/S0002-9440(10)65616-7] [PMID]
  27. Dibaj M, Haghi M, Safaralizadeh R, Saberi A. The role of EZH2 and its regulatory lncRNAs as a serum-based bio- marker in Alzheimer's disease. Mol Biol Rep. 2024; 51(1):866. [DOI:10.1007/s11033-024-09802-0] [PMID]
  28. Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonil- la C. Monge-bonilla, molecular pathogenesis of Alzhei- mer's disease: An update. Ann Neurosci. 2017; 24(1):46-54. [DOI:10.1159/000464422] [PMID]
  29. Neuropathology Group, Medical Research Council Cog- nitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Age- ing Study (MRC CFAS). Lancet. 2001; 357(9251):169-75. [DOI: 10.1016/s0140-6736(00)03589-3] [PMID]
  30. Laiterä T, Kurki MI, Pursiheimo JP, Zetterberg H, Helis- almi S, Rauramaa T, et al. The expression of transthyretin and amyloid-β protein precursor is altered in the brain of idio- pathic normal pressure hydrocephalus patients. J Alzheimers Dis. 2015; 48(4):959-68. [DOI:10.3233/JAD-150268] [PMID]
  31. Jingami N, Asada-Utsugi M, Uemura K, Noto R, Takahashi M, Ozaki A, et al. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease. J Alzheimers Dis. 2015; 45(1):109-15. [DOI:10.3233/JAD-142622] [PMID]
  32. Herukka SK, Rummukainen J, Ihalainen J, von Und Zu Fraunberg M, Koivisto AM, et al. Amyloid-β and Tau Dy- namics in human brain interstitial fluid in patients with sus- pected normal pressure hydrocephalus. J Alzheimers Dis. 2015; 46(1):261-9. [DOI:10.3233/JAD-142862] [PMID]
  33. Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J. Amyloid-beta: A crucial factor in Alzheimer's disease. Med Princ Pract. 2015; 24(1):1-10. [DOI:10.1159/000369101] [PMID]
  34. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The de- velopment of amyloid β protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006; 2006(6):re1. [DOI:10.1126/ sageke.2006.6.re1] [PMID]
  35. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pru- zin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease -one peptide, two pathways. Nat Rev Neurol. 2020; 16(1):30-42. [DOI:10.1038/s41582-019-0281-2] [PMID]
  36. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr, Younkin LH, Suzuki N, Younkin SG. Amyloid beta pro- tein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995; 270(13):7013-6. [DOI: 10.1074/jbc.270.13.7013] [PMID]
  37. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, et al. Peptide compositions of the cerebro- vascular and senile plaque core amyloid deposits of Alzhei- mer′ s disease. Arch Biochem Biophys. 1993; 301(1):41-52. [DOI:10.1006/abbi.1993.1112] [PMID]
  38. Kakuda N, Miyasaka T, Iwasaki N, Nirasawa T, Wada- Kakuda S, Takahashi-Fujigasaki J, et al. Distinct deposition of amyloid-β species in brains with Alzheimer's disease pa- thology visualized with MALDI imaging mass spectrometry. Acta Neuropathol Commun. 2017; 5(1):73.[DOI:10.1186/ s40478-017-0477-x] [PMID]
  39. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pa- thology of Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90(22):10836-40. [DOI:10.1073/pnas.90.22.10836] [PMID]
  40. Attems J, Lintner F, Jellinger KA. Amyloid β peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathol. 2004; 107(4):283-91. [DOI:10.1007/s00401-004-0822-6] [PMID]
  41. Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos RA. Hereditary cerebral hemorrhage with amyloidosis (Dutch): A model for congophilic plaque formation without neurofibrillary pathology. Acta Neuropathol. 1994; 88(4):371- 8. [DOI:10.1007/BF00310382] [PMID]
  42. Mandybur TI. Cerebral amyloid angiopathy: The vascu- lar pathology and complications. J Neuropathol Exp Neurol. 1986; 45(1):79-90. [DOI:10.1097/00005072-198601000-00007]
  43. You Y, Perkins A, Cisternas P, Muñoz B, Taylor X, You Y, et al. Tau as a mediator of neurotoxicity associated to cere- bral amyloid angiopathy. Acta Neuropathol Commun. 2019; 7(1):26. [DOI:10.1186/s40478-019-0680-z] [PMID]
  44. Kim HJ, Park S, Cho H, Jang YK, San Lee J, Jang H, et al. Assessment of extent and role of tau in subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging. JAMA Neurol. 2018; 75(8):999-1007. [DOI:10.1001/jamaneurol.2018.0975] [PMID]
  45. Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, et al. Pulse pressure in relation to tau- mediated neurodegeneration, cerebral amyloidosis, and pro- gression to dementia in very old adults. JAMA Neurol. 2015; 72(5):546-53. [DOI:10.1001/jamaneurol.2014.4477] [PMID]
  46. Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, et al. Tau induces blood vessel abnormalities and angio- genesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A. 2018; 115(6):E1289-98. [DOI:10.1073/pnas.1710329115] [PMID]
  47. Merlini M, Wanner D, Nitsch RM. Tau pathology-depend- ent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy. Acta Neuropathol. 2016; 131(5):737-52. [DOI:10.1007/s00401- 016-1560-2] [PMID]
  48. Castillo-Carranza DL, Nilson AN, Van Skike CE, Jahrling JB, Patel K, Garach P, et al. Cerebral microvascular accumu- lation of tau oligomers in Alzheimer's disease and related tauopathies. Aging Dis. 2017; 8(3):257-66. [DOI:10.14336/ AD.2017.0112] [PMID]
  49. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood-brain barrier P-gly- coprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm (Vienna). 2008; 115(7):1001-9. [DOI:10.1007/s00702-008-0030-y] [PMID]
  50. Komori T. Tau-positive dial Inclusions in Progressive Supra- nuclear Palsy, Corticobasal Degeneration and Pick's disease. Brain Pathol. 1999; 9(4):663-79. [DOI:10.1111/j.1750-3639.1999. tb00549.x] [PMID]
  51. Ransom B, Behar T, Nedergaard M. New roles for as- trocytes (stars at last). Trends Neurosci. 2003; 26(10):520-2. [DOI:10.1016/j.tins.2003.08.006]
  52. Vidal R, Calero M, Piccardo P, Farlow MR, Unverzagt FW, Méndez E, et al. Senile dementia associated with amy- loid beta protein angiopathy and tau perivascular pathol- ogy but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele. Acta Neuropathol. 2000; 100(1):1-12. [DOI:10.1007/s004010051186] [PMID]
  53. J, Daneshvar DH, Kiernan PT, Abdolmohammadi B, Alvarez VE, Huber BR, et al. Clinicopathological evalu- ation of chronic traumatic encephalopathy in players of American football. JAMA. 2017; 318(4):360-70. [DOI:10.1001/ jama.2017.8334] [PMID]
  54. Kanaan NM, Cox K, Alvarez VE, Stein TD, Poncil S, McKee AC. Characterization of early pathological tau conformations and phosphorylation in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2016; 75(1):19-34. [DOI:10.1093/ jnen/nlv001] [PMID]
  55. Cisternas P, Taylor X, Lasagna-Reeves CA. The amyloid- tau-neuroinflammation axis in the context of cerebral amyloid angiopathy. Int J Mol Sci. 2019; 20(24):6319. [DOI:10.3390/ ijms20246319] [PMID]